CD274 and Zika virus infectious disease: Furthermore, ascribed to the lack of humanized mouse models for ZIKV infection [64,65], our study did not include clinically approved PD-1/PD-L1 antibodies such as Nivolumab, Pembrolizumab and Tislelizumab.